Irinotecan

Chemical formula: C₃₃H₃₈N₄O₆  Molecular mass: 586.678 g/mol  PubChem compound: 60838

Therapeutic indications

Irinotecan is indicated for:

Colorectal cancer

Population group: only adults (18 years old or older)

Irinotecan is indicated for the treatment of patients with advanced colorectal cancer:

  • in combination with 5-fluorouracil and folinic acid in patients without prior chemotherapy for advanced disease,
  • as a single agent in patients who have failed an established 5-fluorouracil containing treatment regimen.

Irinotecan in combination with cetuximab is indicated for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing RAS wild-type metastatic colorectal cancer, who had not received prior treatment for metastatic disease or after failure of irinotecan-including cytotoxic therapy.

Irinotecan in combination with 5-fluorouracil, folinic acid and bevacizumab is indicated for first-line treatment of patients with metastatic carcinoma of the colon or rectum.

Irinotecan in combination with capecitabine with or without bevacizumab is indicated for first-line treatment of patients with metastatic colorectal carcinoma.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Irinotecan is contraindicated in the following cases:

Chronic inflammatory bowel disease, bowel obstruction

at least one of
Chronic inflammatory small bowel disease
Intestinal obstruction

Lactation

Lactation

St. John's Wort

Hypericum perforatum (St John's Wort)

Live attenuated vaccines

Live organism vaccines

WHO performance status >2

at least one of
WHO performance status grade 3
WHO performance status grade 4

Severe bone marrow failure

Bone marrow disorder

Bilirubin >3 times the upper limit of the normal range

at least one of
Increased bilirubin level
Hepatic failure stage IV

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2018: CAMPTO Concentrate for solution for infusion
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈